Literature DB >> 14681861

Advanced glycation end products in uremia.

Thomas Henle1, Toshio Miyata.   

Abstract

The term "advanced glycation end products" (AGEs) stands for a heterogeneous group of amino acid derivatives that are formed via glycation processes between peptide-bound lysine or arginine derivatives and carbonyl compounds, processes originally known from food systems as "Maillard reactions." AGEs accumulate in plasma and tissues with advancing age, diabetes, and particular renal failure. In vivo and in vitro studies indicate that AGEs represent an important class of uremic toxins. This review focuses on the chemistry behind the formation of AGEs, possible mechanisms underlying the accumulation of AGEs in uremia, clinical and therapeutic implications, and possible nutritional consequences.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14681861     DOI: 10.1053/j.arrt.2003.08.006

Source DB:  PubMed          Journal:  Adv Ren Replace Ther        ISSN: 1073-4449


  11 in total

1.  Prognostic potential and tumor growth-inhibiting effect of plasma advanced glycation end products in non-small cell lung carcinoma.

Authors:  Babett Bartling; Hans-Stefan Hofmann; Antonia Sohst; Yvonne Hatzky; Veronika Somoza; Rolf-Edgar Silber; Andreas Simm
Journal:  Mol Med       Date:  2011-05-24       Impact factor: 6.354

2.  Immunogenicity of advanced glycation end products in diabetic patients and in nephropathic non-diabetic patients on hemodialysis or after renal transplantation.

Authors:  A M Buongiorno; S Morelli; E Sagratella; R Cipriani; S Mazzaferro; S Morano; M Sensi
Journal:  J Endocrinol Invest       Date:  2008-06       Impact factor: 4.256

3.  Dicarbonyl-mediated protein modifications affect matrix metalloproteinase (MMP) activity.

Authors:  B Bartling; M Desole; R-E Silber; A Simm
Journal:  Z Gerontol Geriatr       Date:  2007-10       Impact factor: 1.281

4.  Advanced glycation end products upregulate lysyl oxidase and endothelin-1 in human aortic endothelial cells via parallel activation of ERK1/2-NF-κB and JNK-AP-1 signaling pathways.

Authors:  Christos Adamopoulos; Christina Piperi; Antonios N Gargalionis; Georgia Dalagiorgou; Eliana Spilioti; Penelope Korkolopoulou; Evanthia Diamanti-Kandarakis; Athanasios G Papavassiliou
Journal:  Cell Mol Life Sci       Date:  2015-12-08       Impact factor: 9.261

5.  Effects of olmesartan on arterial stiffness in rats with chronic renal failure.

Authors:  Yao-Chen Chuang; Ming-Shiou Wu; Yi-Kai Su; Kwang-Ming Fang
Journal:  Cardiovasc Diabetol       Date:  2012-06-13       Impact factor: 9.951

Review 6.  Stirring the Pot: Can Dietary Modification Alleviate the Burden of CKD?

Authors:  Matthew Snelson; Rachel E Clarke; Melinda T Coughlan
Journal:  Nutrients       Date:  2017-03-11       Impact factor: 5.717

Review 7.  Beyond chronic kidney disease: the diagnosis of Renal Disease in the Elderly as an unmet need. A position paper endorsed by Italian Society of Nephrology (SIN) and Italian Society of Geriatrics and Gerontology (SIGG).

Authors:  Filippo Aucella; Andrea Corsonello; Dario Leosco; Giuliano Brunori; Loreto Gesualdo; Raffaele Antonelli-Incalzi
Journal:  J Nephrol       Date:  2019-01-18       Impact factor: 3.902

8.  Advanced glycation end product-induced astrocytic differentiation of cultured neurospheres through inhibition of Notch-Hes1 pathway-mediated neurogenesis.

Authors:  Yijing Guo; Pin Wang; Haixia Sun; Rongrong Cai; Wenqing Xia; Shaohua Wang
Journal:  Int J Mol Sci       Date:  2013-12-23       Impact factor: 5.923

9.  Lysyl oxidase interacts with AGE signalling to modulate collagen synthesis in polycystic ovarian tissue.

Authors:  Katerina K Papachroni; Christina Piperi; Georgia Levidou; Penelope Korkolopoulou; Leszek Pawelczyk; Evanthia Diamanti-Kandarakis; Athanasios G Papavassiliou
Journal:  J Cell Mol Med       Date:  2010-10       Impact factor: 5.310

Review 10.  Role of advanced glycation end products in mobility and considerations in possible dietary and nutritional intervention strategies.

Authors:  Jie-Hua Chen; Xu Lin; Cuihong Bu; Xuguang Zhang
Journal:  Nutr Metab (Lond)       Date:  2018-10-10       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.